Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results

Aligos burns cash rapidly as key clinical data remains nearly a year away.

What the company is saying

Aligos Therapeutics highlights progress in its clinical pipeline, emphasizing the completed enrollment of its Phase 2 B-SUPREME study for pevifoscorvir sodium and the advancement of ALG-170675 into Phase 1 studies in China with partner Amoytop. The company frames its narrative around being 'one step closer' to effective HBV therapies, with topline data for the B-SUPREME study expected in late Q3 2027. Management, led by CEO Lawrence Blatt, signals confidence in the pipeline's potential but acknowledges that Amoytop funds development costs for ALG-170675 in China, with each party responsible for their own expenses. The announcement stresses a reduction in R&D expenses due to lower third-party costs for the Phase 2 trial, but also notes increased G&A expenses from higher legal and related costs. Aligos asserts that its $31.1 million in cash and investments will fund operations into Q1 2027, but does not announce any new financing or partnership deals.

What the data suggests

Aligos' liquidity position has deteriorated sharply, with cash, cash equivalents, and investments falling from $77.8 million at December 31, 2025 to $31.1 million at September 30, 2026. Net loss for Q3 2026 was $21.9 million, an improvement from $31.5 million in Q3 2025, but operating expenses for the nine months ended September 30, 2026 rose to $84.2 million from $68.2 million in the prior-year period. Revenue remains negligible, with just $2,830 from customers and $39 from licensing in Q3 2026. Total assets dropped to $47.2 million from $88.5 million, and stockholders’ equity fell to $11.3 million from $53.5 million over the same period. The company’s cash runway is projected to last only into Q1 2027, less than six months from the announcement date and well before any pivotal clinical data is expected. The reduction in R&D expenses is attributed to lower third-party costs for the B-SUPREME trial, but G&A expenses increased due to legal and related costs. The company’s financial disclosures are detailed and transparent, but the numbers point to a precarious funding situation.

Analysis

The announcement is measured in tone and provides detailed, transparent financial and operational disclosures. Most claims are realised and supported by specific data, such as completed enrollment in the Phase 2 B-SUPREME study, cash position, and net loss figures. Forward-looking statements are limited and factual, primarily relating to the expected topline data in late Q3 2027 and the sufficiency of cash into Q1 2027. The company is still pre-commercial, with minimal revenue and ongoing significant R&D spend, and the main clinical catalyst is over 9 months away, indicating a long execution distance. The capital intensity flag is true, as substantial R&D outlays continue with no near-term revenue or profit impact. There is no evidence of narrative inflation or exaggerated claims; language is proportionate to progress.

Risk flags

• ●Aligos faces acute liquidity risk, with cash, cash equivalents, and investments of $31.1 million as of September 30, 2026 and a projected runway only into Q1 2027. This is well before the next clinical catalyst, making a dilutive financing or partnership highly likely.
• ●The company’s operating expenses remain high, with $84.2 million spent in the first nine months of 2026 and only minor reductions in R&D costs. Sustained high burn without offsetting revenue or capital raises increases the risk of financial distress.
• ●Key clinical milestones are long-dated, with topline data for the B-SUPREME study not expected until late Q3 2027. This long execution gap heightens the risk that interim setbacks or delays could further erode investor confidence and financial flexibility.
• ●Revenue remains negligible, with just $2,830 from customers and $39 from licensing in Q3 2026, underscoring the company’s dependence on external funding and the absence of near-term commercial prospects.

Bottom line

Aligos Therapeutics is advancing its HBV pipeline but remains a pre-commercial, cash-burning biotech with no meaningful revenue and a shrinking cash reserve. The company’s $31.1 million in cash and investments will only fund operations into Q1 2027, while the next major clinical readout is not due until late Q3 2027, leaving a clear funding gap. Management’s confidence in the pipeline is not matched by near-term catalysts or financial strength, and the absence of new partnerships or financing announcements increases the likelihood of dilution or other capital-raising measures. Investors should focus on the company’s ability to secure new funding in the coming months, as this will determine whether it can bridge the gap to potentially value-creating clinical data. The most important takeaway is that Aligos must address its funding shortfall well before topline data can drive any re-rating.

Announcement summary

(NASDAQ:ALGS) Aligos Therapeutics, Inc. reported recent business progress and financial results for the third quarter of 2026. The company continued to advance its Phase 2 B-SUPREME study of pevifoscorvir sodium, with enrollment now complete and 70 participants having completed 48 weeks of treatment. The B-SUPREME study (NCT06963710) enrolled 131 participants in the HBeAg+ cohort (Part 1a) and 114 participants in the HBeAg- cohort (Part 2a), with topline data for both cohorts expected in late Q3 2027. Aligos' partner Amoytop advanced ALG-170675, a potential best-in-class antisense oligonucleotide (ASO) for chronic hepatitis B virus (HBV) infection, into Phase 1 clinical studies in China, with Amoytop funding current development costs and maintaining rights in Greater China. Aligos may utilize data from these studies for regulatory filings and other purposes, and each party is responsible for their own development costs. As of September 30, 2026, cash, cash equivalents, and investments totaled $31.1 million, compared with $77.8 million as of December 31, 2025. The company expects its cash and cash equivalents to provide sufficient funding of planned operations into the first quarter of 2027. For the three months ended September 30, 2026, net loss was $21.9 million, or basic and diluted net loss per common share of $(2.09), compared to a net loss of $31.5 million, or $(3.04) per share, for the same period in 2025. Research and development (R&D) expenses for the three months ended September 30, 2026 were $18.9 million, compared with $23.9 million for the same period of 2025, primarily due to a decrease in third-party expenses for the pevifoscorvir sodium Phase 2 clinical trial. Total R&D stock-based compensation expense for the three months ended September 30, 2026 was $0.6 million, compared with $0.8 million for the same period of 2025. General and administrative (G&A) expenses for the three months ended September 30, 2026 were $5.9 million, compared with $5.2 million for the same period of 2025, with the increase primarily due to higher legal and related expenses. Total G&A stock-based compensation expense for the three months ended September 30, 2026 was $0.6 million, compared with $0.7 million for the same period of 2025. Interest and other income, net, was $0.2 million for the three months ended September 30, 2026, compared with $1.1 million for the same period in 2025. Change in fair value of 2023 common warrants for the three months ended September 30, 2026 was income of $0.2 million, compared with a loss of $4.2 million for the same period of 2025. Revenue from customers for the three months ended September 30, 2026 was $2,830, and revenue from licensing agreements was $39. For the nine months ended September 30, 2026, revenue from customers was $5,660 and revenue from licensing agreements was $27,817. Operating expenses for the three months ended September 30, 2026 were $24,759, and for the nine months ended September 30, 2026 were $84,186. Loss from operations for the three months ended September 30, 2026 was $21,890, and for the nine months ended September 30, 2026 was $50,709. Net loss for the nine months ended September 30, 2026 was $46,404. As of September 30, 2026, total assets were $47,189, total liabilities were $35,883, and total stockholders’ equity was $11,306.

Disagree with this article?